Zhengye Biotechnology Holdings/$ZYBT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zhengye Biotechnology Holdings
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
Ticker
$ZYBT
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
278
ISIN
KYG989MS1016
Website
ZYBT Metrics
BasicAdvanced
$383M
130.91
$0.06
-
-
Price and volume
Market cap
$383M
52-week high
$14.30
52-week low
$3.50
Average daily volume
641K
Financial strength
Current ratio
1.381
Quick ratio
0.729
Total debt to equity
24.983
Dividend payout ratio (TTM)
183.91%
Interest coverage (TTM)
7.07%
Profitability
EBITDA (TTM)
7.498
Gross margin (TTM)
55.51%
Net profit margin (TTM)
10.69%
Operating margin (TTM)
16.11%
Effective tax rate (TTM)
18.69%
Revenue per employee (TTM)
$94,590
Management effectiveness
Return on assets (TTM)
3.82%
Return on equity (TTM)
7.15%
Valuation
Price to earnings (TTM)
130.909
Price to revenue (TTM)
13.996
Price to book
1.31
Price to tangible book (TTM)
1.44
Price to free cash flow (TTM)
92.777
Free cash flow yield (TTM)
1.08%
Free cash flow per share (TTM)
8.72%
Growth
Revenue change (TTM)
-25.23%
Earnings per share change (TTM)
-53.70%
Bulls say / Bears say
Zhengye Biotechnology Holding Limited successfully closed its initial public offering on January 8, 2025, raising $6 million to fund acquisitions and R&D projects, potentially driving future growth. (globenewswire.com)
The company's focus on livestock vaccines positions it well within China's large agricultural sector, offering significant market opportunities. (globenewswire.com)
Zhengye's portfolio of 44 products available domestically and internationally indicates a diversified revenue stream and potential for market expansion. (quiverquant.com)
The company reported a 25.23% year-over-year decline in revenue for the trailing twelve months ending June 2024, indicating potential challenges in maintaining sales growth. (stockanalysis.com)
Net income decreased by 53.70% in the same period, reflecting significant profitability concerns. (stockanalysis.com)
Zhengye's cash and equivalents dropped by 63.81% as of June 2024, which may impact its ability to fund operations and growth initiatives. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jun 2025.
ZYBT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zhengye Biotechnology Holdings stock?
Zhengye Biotechnology Holdings (ZYBT) has a market cap of $383M as of June 20, 2025.
What is the P/E ratio for Zhengye Biotechnology Holdings stock?
The price to earnings (P/E) ratio for Zhengye Biotechnology Holdings (ZYBT) stock is 130.91 as of June 20, 2025.
Does Zhengye Biotechnology Holdings stock pay dividends?
No, Zhengye Biotechnology Holdings (ZYBT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Zhengye Biotechnology Holdings dividend payment date?
Zhengye Biotechnology Holdings (ZYBT) stock does not pay dividends to its shareholders.
What is the beta indicator for Zhengye Biotechnology Holdings?
Zhengye Biotechnology Holdings (ZYBT) does not currently have a Beta indicator.